{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The percentage of patients who achieve confirmed CR or PR or SD ≥12 weeks following study treatment initiation.","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"OG000","title":"Experimental: Nab-Sirolimus"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"through study completion (up to 72 months)","title":"Disease Control Rate","type":"POST_HOC","unitOfMeasure":"Participants"}